References :
[1] Moake JL. Thrombotic microangiopathies. N Engl J Med.2002;347:589-600.
[2] Kremer Hovinga JA, Coppo P, Lämmle B, Moake JL, Miyata T, Vanhoorelbeke K. Thrombotic thrombocytopenic purpura. Nat Rev Dis Primers . 2017;3:17020.
[3] Thornsberry LA, LoSicco KI, English JC 3rd. The skin and hypercoagulable states. J Am Acad Dermatol . 2013;69:450-462.
[4] Mariotte E, Azoulay E, Galicier L, Rondeau E, Zouiti F, Boisseau P et al. French Reference Center for Thrombotic Microangiopathies. Epidemiology and pathophysiology of adulthood-onset thrombotic microangiopathy with severe ADAMTS13 deficiency (thrombotic thrombocytopenic purpura): a cross-sectional analysis of the French national registry for thrombotic microangiopathy. Lancet Haematol . 2016;3:237-45.
[5] Mancini I, Pontiggia S, Palla R, Artoni A, Valsecchi C, Ferrari B et al. Clinical and Laboratory Features of Patients with Acquired Thrombotic Thrombocytopenic Purpura: Fourteen Years of the Milan TTP Registry. Thromb Haemost . 2019;119:695-704.
[6] Becker S, Fusco G, Fusco J, Balu R, Gangjee S, Brennan C et al. HIV-associated thrombotic microangiopathy in the era of highly active antiretroviral therapy: an observational study. Clin Infect Dis.2004;39:267-75.
[7]Cheah CY, De Keulenaer B, Leahy MF. Fluoroquinolone-induced immune thrombocytopenia: a report and review. Intern Med J . 2009;39:619-623.
[8]Hashmi HR, Diaz-Fuentes G, Jadhav P, Khaja M. Ciprofloxacin-Induced Thrombotic Thrombocytopenic Purpura: A Case of Successful Treatment and Review of the Literature. Case Rep Crit Care . 2015;2015:1-4.
[9] Rock GA, Shumak KH, Buskard NA, Blanchette VS, Kel-ton JG, Nair RC, et al. Comparison of plasma exchange with plasma infusion in the treatment of thrombotic thrombocytopenic purpura. N Engl J Med. 1991;325:393–7.
[10]Matsumoto M, Fujimura Y, Wada H, Kokame K, Miyakawa Y, Ueda Y et al. Diagnostic and treatment guidelines for thrombotic thrombocytopenic purpura (TTP) 2017 in Japan. Int J Hematol . 2017;106:3-15.
[11]Fakhouri F, Vernant JP, Veyradier A, Wolf M, Kaplanski G, Binaut R et al. Efficiency of curative and prophylactic treatment with rituximab in ADAMTS13-deficient thrombotic thrombocytopenic
purpura: a study of 11 cases. Blood . 2005;106:1932-7.
[12]Said A, Haddad RY, Stein R, Lerma EV. Thrombotic thrombocytopenic purpura. Dis Mon . 2014;60:500-504.